CTIS2023-506837-31-00进行中（未招募）1 期
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE) - TCD601F201
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Itb-Med AB
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Able to understand the study requirements and provide written informed consent before any study assessment is performed., Male or female between 18 to 45 years of age., A diagnosis of T1D by a qualified healthcare provider based on ADA guidelines = 100 days of randomization., Positive for at least one diabetes-related autoantibody against: Glutamate decarboxylase (GAD-65), Insulin, if obtained prior and up to 10 days of the onset of exogenous insulin therapy, Insulinoma antigen-2 (IA-2), Zinc transporter-8 (ZnT8), or Islet cell autoantibodies against cytoplasmic proteins in the beta cell (ICA)., Peak stimulated C-peptide level >0.2 pmol/mL (200 pmol/L) following a two-hour mixed-meal tolerance test (MMTT) during Screening (Visit 1)., Agreement to follow local, regional, or national guidelines for strict glycemic control with targets of HbA1c = 53 mmol/mol (= 7.0%)., Agreement to use CGM from screening until the end of the study/Week 52, Up to date immunization status or agreement to receive routine immunizations according to current country and/or regional guidelines and agree to comply with the guidelines for immunosuppressed individuals and those with chronic disease prior to randomization and receipt of study drug.
排除标准
- •Inability or unwillingness to provide written informed consent or comply with the study protocol., Previous or current diagnosis of malignancy, except adequately treated cervical carcinoma in situ and adequately treated non-metastatic basal and squamous cell carcinoma., History of bone marrow transplantation (BMT) / stem cell transplantation or solid organ transplantation., History or diagnoses of other autoimmune disease, including disease associated with lymphopenia, with the exception of stable thyroid or celiac disease., History of significant cardiovascular disease (including history of myocardial infarction, angina, use of anti-anginal medicines (e.g., nitroglycerin), or abnormal stress test)., Vaccination with a live attenuated vaccine (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, bacillus Calmette- Guérin, and smallpox) within 28 days of dosing (Day 0)., Past or current medical problems or findings from physical examination or laboratory testing, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant’s ability to comply with study requirements or that may affect the quality or interpretation of the data obtained from the study., Current diagnosed mental illness (e.g., severe depression), current diagnosed or self-reported drug, or alcohol abuse that, in the opinion of the investigator, would interfere with the participant’s ability to comply with study requirements., Women who are pregnant, lactating, or planning on pregnancy during the study., Women of child-bearing potential who are unwilling to use a medically acceptable form of contraception until study Week 52. Contraception is required for 14 days prior to randomization. Highly effective contraception methods include: • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. • Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject. • Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example, hormone vaginal ring or transdermal hormone contraception. • Placement of long-acting reversible contraceptives or intrauterine device or intrauterine system. In case of use of oral contraception women should have been stable on the same brand (or generic equivalent) for a minimum of 3 months before taking study treatment. Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to screening. In the case of oophorectomy alone, only when the reproductive status of the woman has been co
研究者
相似试验
进行中（未招募）
1 期
A 12-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 after 4- and 12-weeks of treatment in patients with coronary artery disease (CAD)Coronary artery diseaseEUCTR2017-001582-25-FIAstraZeneca AB200
进行中（未招募）
1 期
A 12-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 after 4- and 12-weeks of treatment in patients with coronary artery disease (CAD)EUCTR2017-001582-25-DKAstraZeneca AB200
招募中
2 期
Head Injury and TestosteroneTraumatic Brain InjuryNeurological - Other neurological disordersInjuries and Accidents - Other injuries and accidentsACTRN12613001219774The McCusker Alzheimer's Research Foundation80
进行中（未招募）
不适用
A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPFIdiopathic pulmonary fibrosisEUCTR2006-002875-42-BESCS Boehringer Ingelheim Comm.V400
进行中（未招募）
不适用
A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPFIdiopathic pulmonary fibrosisEUCTR2006-002875-42-BGBoehringer Ingelheim Pharma Ges mbH400